TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05438875
Drug: all-trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
Study: NCT05438875
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
Study: NCT00005768
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05961410
Drug: Eltrombopag olamine
Normalized name: Eltrombopag Olamine
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
Study: NCT05210101
Drug: Sotrovimab
Normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
Study: NCT05088889
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab administered IV over 30 minutes at a dose of 360mg every 3 weeks
Study: NCT05088889
Drug: ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab administered IV over 30 minutes at 1 mg/kg every 6 weeks
Study: NCT05272696
Drug: Nab-paclitaxel, cisplatin and Pembrolizumab combination
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy
Study: NCT05116306
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
Study: NCT05133050
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
Study: NCT06064864
Drug: Infliximab-Dyyb
Normalized name: infliximab-dyyb
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
Study: NCT05319249
Drug: Talazoparib 1 MG [Talzenna]
Normalized name: talazoparib 1 MG [Talzenna]
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
Study: NCT06511570
Drug: sabirnetug (ACU193)
Normalized name: Sabirnetug
DrugBank: Sabirnetug (DB19438)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sabirnetug by intravenous infusion
Study: NCT06434467
Drug: Nelarabine injection
Normalized name: nelarabine Injection
DrugBank: Nelarabine (DB01280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.
Study: NCT05146635
Drug: Intravesical Bcg
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive induction and maintenance BCG after complete TURBT.
Study: NCT05146635
Drug: Intravesical chemotherapy (epirubicin)
Normalized name: Valrubicin Intravesical Solution
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive induction and maintenance epirubicin after complete TURBT.
Study: NCT02562612
Drug: SM-88
Normalized name: Sm-88 component racemetyrosine
DrugBank: Racemetyrosine (DB16306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SM-88 in multiple ascending doses over 6 months
Study: NCT06212661
Drug: Ubrogepant
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study: NCT06212661
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study: NCT06212661
Drug: Atogepant
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study: NCT06212661
Drug: Eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study: NCT06212661
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study: NCT06212661
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study: NCT06212661
Drug: Erenumab
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Study: NCT05326308
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: according to the Summary of Product Characteristics (SmPC).
Study: NCT05326308
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: according to the Summary of Product Characteristics (SmPC).
Study: NCT06212661
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
Study: NCT06293040
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis will be vaporized using the Mighty Medic
Study: NCT06293040
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol will be orally ingested via a flavored drink
Study: NCT06293040
Drug: Placebo Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.
Study: NCT05108740
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self-administered as a daily dose of 10mg orally
Study: NCT04278235
Drug: Elezanumab
Normalized name: Elezanumab
DrugBank: Elezanumab (DB15240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous (IV) infusion
Study: NCT05027048
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description above
Study: NCT04828226
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.
Study: NCT05901012
Drug: N,N-Dimethyltryptamine
Normalized name: N,N-dimethyltryptamine
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
Study: NCT06339411
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin post-mechanical thrombectomy, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.
Study: NCT05315700
Drug: ORIC-114
Normalized name: Oriconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ORIC-114 oral daily
Study: NCT05315700
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 days for up to 4 cycles
Study: NCT06647602
Drug: Euthyrox (levothyroxine)
Normalized name: levothyroxine Oral Tablet [Euthyrox]
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.
Study: NCT06647602
Drug: Cytomel (liothyronine)
Normalized name: liothyronine Oral Tablet [Cytomel]
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The pharmacoequivalent ratio of L-T3 to L-T4 is 1:3. The L-T4-cohort receive doses of 2 μg × kg body weight / day. The pharmacoequivalent L-T3 dose would be 1/3th of that namely: 0.67 μg × kg body weight / day. Cytomel will be given trice daily and available dosages are 5, 12.5 and 25 μg.
Study: NCT05353582
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
Study: NCT05353582
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
Study: NCT06665425
Drug: Epaminurad 9 mg
Normalized name: Epaminurad
DrugBank: Epaminurad (DB18973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
Study: NCT06665425
Drug: C2406
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
Study: NCT00001004
Drug: Interferon gamma-1b
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06619522
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT04887935
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -The 10 mg dose is reflective of current clinical practice for diabetes and heart failure
Study: NCT02012933
Drug: 3,4-diaminopyridine
Normalized name: 3,4-Diaminopyridine
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10mg tablets for up to 100mg per day
Study: NCT05116202
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
Study: NCT05116202
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
Study: NCT05116202
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
Study: NCT05116202
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
Study: NCT05109442
Drug: AFM24
Normalized name: Amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion
Study: NCT05109442
Drug: Atezolizumab 840 MG in 14 ML Injection
Normalized name: atezolizumab 840 MG in 14 ML Injection
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous infusion
Study: NCT06649409
Drug: Vamorolone
Normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vamorolone 20 mg/kg single dose on Day 2
Study: NCT06649409
Drug: Fludrocortisone
Normalized name: Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm.
Study: NCT05397171
Drug: Zirconium-89 crefmirlimab berdoxam
Normalized name: zirconium
DrugBank: Crefmirlimab (DB17577)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853
Study: NCT04873453
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
Study: NCT05721846
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle
Study: NCT05721846
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)
Study: NCT06275841
Drug: vepdegestrant
Normalized name: Vepdegestrant
DrugBank: Vepdegestrant (DB19006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental
Study: NCT06275841
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental treatment to assess an endpoint
Study: NCT06246968
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Pembrolizumab as part of standard of care treatment.
Study: NCT06621563
Drug: HS-20117 combined Platinum-containing chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-20117 + cisplatin/carboplatin + pemetrexed
Study: NCT06621563
Drug: HS-20117 combined HS-20093 and 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HS-20117 + HS-20093 + 5-FU
Study: NCT05763875
Drug: Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
Study: NCT05763875
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
Study: NCT05763875
Drug: Matching Placebo for Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
Study: NCT05763875
Drug: Matching Placebo for Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
Study: NCT04532645
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib
Study: NCT00163982
Drug: Norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06649240
Drug: Statins and/or Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Statin ± Ezetimibe to achieve target LDL-cholesterol level
Study: NCT06575179
Drug: Dexmedetomidine low-dose
Normalized name: ethinyl estradiol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The low-dose dexmedetomidine group received a 75 μg/h loading dose over 15 minutes, followed by 60 μg/h maintenance infusion intravenously.
Study: NCT06575179
Drug: Dexmedetomidine high-dose
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The high-dose dexmedetomidine group received a 150 μg/h loading dose over 15 minutes, followed by 120 μg/h maintenance infusion intravenously.
Study: NCT05670925
Drug: Camrelizumab plus Famitinib with/without nab-Palitaxel
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
Study: NCT06667154
Drug: Low-dose nivolumab combined with platinum-based doublet chemotherapy
Normalized name: ethinyl estradiol
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3 mg/kg every 21 days for 3 cycles.
Study: NCT05412290
Drug: Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following.
Study: NCT05759624
Drug: rhGH
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
Study: NCT06473597
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NURTEC ODT 75 mg orally disintegrating tablets
Study: NCT06473597
Drug: Rizatriptan Benzoate
Normalized name: Rizatriptan Benzoate
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rizatriptan ODT 10mg orally disintegrating tablets
Study: NCT04852679
Drug: Lanreotide autogel
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as deep subcutaneous (SC) injections
Study: NCT04709185
Drug: Dexamethasone 1 MG Oral Tablet
Normalized name: DEXAMETHASONE 1 mg ORAL TABLET
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
Study: NCT06252454
Drug: Furosemide 40 mg
Normalized name: furosemide 40 MG
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.
Study: NCT06252454
Drug: Levodropropizine
Normalized name: levodropropizine
DrugBank: Levodropropizine (DB12472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation
Study: NCT05098067
Drug: Capsaicin Topical Cream
Normalized name: capsaicin Topical Cream
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5g 0.075% applied once
Study: NCT05098067
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg IV once
Study: NCT05098067
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8mg IV once if needed
Study: NCT02411604
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.